Predictors of mortality post-gastrostomy in motor neuron disease patients.
gastrostomy
motor neuron disease
predictor
short survival
weight
Journal
Muscle & nerve
ISSN: 1097-4598
Titre abrégé: Muscle Nerve
Pays: United States
ID NLM: 7803146
Informations de publication
Date de publication:
06 Sep 2024
06 Sep 2024
Historique:
revised:
19
08
2024
received:
07
04
2024
accepted:
21
08
2024
medline:
6
9
2024
pubmed:
6
9
2024
entrez:
6
9
2024
Statut:
aheadofprint
Résumé
Motor neuron disease (MND) is a progressive neurodegenerative condition with a limited life expectancy. There is very little data on mortality and its associated factors beyond 30 days following gastrostomy. We explored the demographic, clinical, and nutritional predictors for early mortality at 30, 90, and 180 days following gastrostomy in these patients. This was a retrospective study involving 94 MND patients in Western Australia who underwent gastrostomy between 2015 and 2021. Patients were divided into two groups based on mortality at 30, 90, and 180 days post-gastrostomy. T-test (or Mann-Whitney), chi-square test and Fisher's exact test were used for detecting between-group differences in various factors. Multivariable logistic regression was used to identify factors associated with post-gastrostomy mortality at 90 and 180 days. No mortality was attributable to gastrostomy-related complications. Lower forced vital capacity (FVC) (p = .039) and greater weight loss (%) (p = .022) from diagnosis to gastrostomy were observed in those who died within 30 days post-gastrostomy. Older age (p = .022), male sex (p = .041), lower FVC (p = .04), requiring but not tolerating noninvasive ventilation (p = .035), and greater weight loss (%) (p = .012) were independent predictors of 90-day post-gastrostomy mortality. However, only older age (p = .01) and greater weight loss (p = .009) were predictors of mortality at 180 days post-gastrostomy. Our data indicated that mortality at 90 and 180 days was influenced by the weight loss (%) from diagnosis to gastrostomy, highlighting the importance of nutritional care in the MND population. Gastrostomy placement prior to substantial weight loss may reduce the risk of weight loss-associated mortality and warrants further investigation.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Western Australian Health Translation Network Enabling Allied Health Research Capacity grant provided by the Chief Allied Health Office through the Allied Health Enabling Platform
Organisme : Australian Government Research Training Program
Organisme : Curtin University of Technology
Informations de copyright
© 2024 The Author(s). Muscle & Nerve published by Wiley Periodicals LLC.
Références
Burgos R, Bretón I, Cereda E, et al. ESPEN guideline clinical nutrition in neurology. Clin Nutr. 2018;37(1):354‐396. doi:10.1016/j.clnu.2017.09.003
National Clinical Guideline C. National Institute for Health and Care Excellence: clinical guidelines. Motor neurone disease: assessment and management. National Clinical Guideline Centre. 2016.
Progas Study G. Gastrostomy in patients with amyotrophic lateral sclerosis (Progas): a prospective cohort study. Lancet Neurol. 2015;14(7):702‐709. doi:10.1016/S1474‐4422(15)00104‐0
Diagnosis ETFo, Sclerosis: MoAL, Andersen P, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)—revised report of an EFNS task force. Eur J Neurol. 2012;19(3):360‐375. doi:10.1111/j.1468‐1331.2011.03501.x
Brotherton AM, Abbott J. Patient perceptions of clinical decision making for percutaneous endoscopic gastrostomy placement. J Hum Nutr Diet. 2008;21(23):382‐383. doi:10.1111/j.1365‐277X.2008.00881_13.x
Kato C, Morimoto S, Takahashi S, et al. Influence of a clinical trial in the decision‐making processes of patients with amyotrophic lateral sclerosis. J Neurol. 2021;269(5):2634‐2640. doi:10.1007/s00415‐021‐10862‐6
Martin NH, Landau S, Janssen A, et al. Psychological as well as illness factors influence acceptance of non‐invasive ventilation (NIV) and gastrostomy in amyotrophic lateral sclerosis (ALS): a prospective population study. Amyotroph Lateral Scler Frontotemp Degener. 2014;15(5–6):376‐387. doi:10.3109/21678421.2014.886700
White S, O'Cathain A, Halliday V, Croot L, McDermott CJ. Factors influencing decisions people with motor neuron disease make about gastrostomy placement and ventilation: a qualitative evidence synthesis. Health Expect. 2023;26(4):1418‐1435. doi:10.1111/hex.13786
Bond L, Ganguly P, Khamankar N, et al. A comprehensive examination of percutaneous endoscopic gastrostomy and its association with amyotrophic lateral sclerosis patient outcomes. Brain Sci. 2019;9(9):223.
Stavroulakis H, Baird W, Baxter S, et al. Factors influencing decision‐making in relation to timing of gastrostomy insertion in patients with motor Neurone disease. BMJ Support Palliat Care. 2014;4:57‐63. doi:10.1136/bmjspcare‐2013‐000497
White S, O'Cathain A, Halliday V, et al. Supporting people with motor neuron disease (MND) to make decisions about gastrostomy feeding tube placement: a survey of UK healthcare professionals' practice and beliefs. Amyotroph Lateral Scler Frontotemp Degener. 2024;25(3–4):290‐298. doi:10.1080/21678421.2024.2314061
Carbo Perseguer J, Madejon Seiz A, Romero Portales M, et al. Percutaneous endoscopic gastrostomy in patients with amyotrophic lateral sclerosis: mortality and complications. Neurologia. 2019;34(9):582‐588. doi:10.1016/j.nrl.2018.01.003
Elbe P, Markus K, Valente R, Ingre C, Tsolakis AV, Vujasinovic M. Effectiveness of percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis. Minerva Gastroenterol Dietol. 2020;66(3):219‐224. doi:10.23736/S1121‐421X.20.02695‐1
Fasano A, Fini N, Ferraro D, et al. Percutaneous endoscopic gastrostomy, body weight loss and survival in amyotrophic lateral sclerosis: a population‐based registry study. Amyotroph Lateral Scler Frontotemp Degener. 2017;18(3–4):233‐242. doi:10.1080/21678421.2016.1270325
Hesters A, Amador MDM, Debs R, et al. Predictive factors for prognosis after gastrostomy placement in routine non‐invasive ventilation users Als patients. Sci Rep. 2020;10(1):15117. doi:10.1038/s41598‐020‐70422‐2
Kasarskis EJ, Scarlata D, Hill R, Fuller C, Stambler N, Cedarbaum JM. A retrospective study of percutaneous endoscopic gastrostomy in ALS patients during the BDNF and CNTF trials. J Neurol Sci. 1999;169(1–2):118‐125. doi:10.1016/S0022‐510X(99)00230‐0
Nagashima K, Furuta N, Makioka K, Fujita Y, Ikeda M, Ikeda Y. An analysis of prognostic factors after percutaneous endoscopic gastrostomy placement in Japanese patients with amyotrophic lateral sclerosis. J Neurol Sci. 2017;376:202‐205. doi:10.1016/j.jns.2017.03.029
Pena MJ, Ravasco P, Machado M, et al. What is the relevance of percutaneous endoscopic gastrostomy on the survival of patients with amyotrophic lateral sclerosis? Amyotroph Lateral Scler. 2012;13(6):550‐554. doi:10.3109/17482968.2012.684215
Strijbos D, Keszthelyi D, Gilissen LPL, et al. Percutaneous endoscopic versus radiologic gastrostomy for enteral feeding: a retrospective analysis on outcomes and complications. Endosc Int Open. 2019;7(11):E1487‐E1495. doi:10.1055/a‐0953‐1524
Forbes RB, Colville S, Swingler RJ. Frequency, timing and outcome of gastrostomy tubes for amyotrophic lateral sclerosis/motor neurone disease—a record linkage study from the Scottish Motor Neurone Disease Register. J Neurol. 2004;251(7):813‐817. doi:10.1007/s00415‐004‐0429‐9
Strijbos D, Hofstede J, Keszthelyi D, Masclee AAM, Gilissen LPL. Percutaneous endoscopic gastrostomy under conscious sedation in patients with amyotrophic lateral sclerosis is safe—an observational study. Eur J Gastroenterol Hepatol. 2017;29(11):1303‐1308. doi:10.1097/meg.0000000000000959
Strong MJ, Rowe A, Rankin RN. Percutaneous Gastrojejunostomy in amyotrophic lateral sclerosis. J Neurol Sci. 1999;169(1–2):128‐132. doi:10.1016/s0022‐510x(99)00235‐x
Yang J, Zhao Y, Soares M, Needham M, Begley A, Calton E. Clinical prognostic factors predicting survival of motor neuron disease patients with gastrostomy: a retrospective analysis. Muscle Nerve. 2024;69(4):440‐447. doi:10.1002/mus.28064
Bokuda K, Shimizu T, Imamura K, et al. Predictive factors for prognosis following unsedated percutaneous endoscopic gastrostomy in ALS patients. Muscle Nerve. 2016;54(2):277‐283. doi:10.1002/mus.25051
Gorrie GH, Chandran S, Colville S, et al. Improved survival and 30‐day mortality after gastrostomy in Scottish motor Neurone disease patients: evidence from a National Retrospective Cohort Study Using Strobe Criteria. Amyotroph Lateral Scler Frontotemp Degener. 2019;20(3–4):165‐171. doi:10.1080/21678421.2019.1570271
Castanheira A, Swash M, de Carvalho M. Percutaneous gastrostomy in amyotrophic lateral sclerosis: a review. Amyotroph Lateral Scler Frontotemp Degener. 2021;23:176‐189. doi:10.1080/21678421.2021.1946089
Berlowitz DJ, Howard ME, Fiore JF, et al. Identifying who will benefit from non‐invasive ventilation in amyotrophic lateral sclerosis/motor neurone disease in a clinical cohort. J Neurol Neurosurg Psychiatry. 2016;87(3):280‐286. doi:10.1136/jnnp‐2014‐310055
Limousin N, Blasco H, Corcia P, et al. Malnutrition at the time of diagnosis is associated with a shorter disease duration in ALS. J Neurol Sci. 2010;297(1–2):36‐39. doi:10.1016/j.jns.2010.06.028
Rio A, Ellis C, Shaw C, et al. Nutritional factors associated with survival following enteral tube feeding in patients with motor neurone disease. J Hum Nutr Diet. 2010;23(4):408‐415. doi:10.1111/j.1365‐277X.2010.01057.x
Vergonjeanne M, Fayemendy P, Marin B, et al. Predictive factors for gastrostomy at time of diagnosis and impact on survival in patients with amyotrophic lateral sclerosis. Clin Nutr. 2020;39(10):3112‐3118. doi:10.1016/j.clnu.2020.01.018
Chiò A, Finocchiaro E, Meineri P, et al. Safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS. Neurology. 1999;53(5):1123‐1125. doi:10.1212/WNL.53.5.1123